Last quarter (Q1 2023), Alnylam Pharma's total revenue was $319.29M, an increase of 49.72% from the same quarter last year. In Q1, Alnylam Pharma's net income was $-174.10M. See Alnylam Pharma’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	$ 1.41B	$ 8.18M	$ 844.29M	$ 492.85M	$ 219.75M	$ 74.91M
Cost of Revenue	$ 188.06M	$ -140.17M	$ 140.14M	$ 78.05M	$ 25.06M	$ 1.80M
Gross Profit	$ 1.22B	$ 1.77B	$ 704.14M	$ 414.80M	$ 194.69M	$ 73.11M
Operating Expense	$ 1.74B	$ 1.65B	$ 1.41B	$ 1.24B	$ 1.13B	$ 887.78M
Operating Income	$ -523.76M	$ 117.43M	$ -708.65M	$ -828.44M	$ -939.43M	$ -814.67M
Net Non Operating Interest Income Expense	$ -115.20M	$ -155.97M	$ -141.44M	$ -72.69M	$ 33.45M	$ 29.26M
Other Income Expense	$ -157.18M	$ 185.95M	$ -2.05M	$ 45.52M	$ 20.73M	$ 24.74M
Pretax Income	$ -795.61M	$ -1.13B	$ -852.14M	$ -855.60M	$ -885.25M	$ -760.67M
Tax Provision	$ 4.92M	$ 4.16M	$ 680.00K	$ 2.68M	$ 863.00K	$ 823.00K
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -800.53M	$ -228.65M	$ -852.82M	$ -858.28M	$ -886.12M	$ -761.50M
Basic EPS	$ -8.70	$ -9.30	$ -7.20	$ -7.46	$ -8.11	$ -7.57
Diluted EPS	$ -8.70	$ -9.30	$ -7.20	$ -7.46	$ -8.11	$ -7.57
Basic Average Shares	$ 488.86M	$ 121.69M	$ 118.45M	$ 114.99M	$ 109.26M	$ 100.59M
Diluted Average Shares	$ 488.86M	$ 121.69M	$ 118.45M	$ 114.99M	$ 109.26M	$ 100.59M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	$ -6.14	$ -6.38	$ -6.70	$ -6.21
Reported Normalized Diluted E P S	-	-	$ -6.14	$ -6.38	$ -6.70	$ -6.21
Rent Expense Supplemental	$ 63.11M	-	-	-	-	-
Total Expenses	$ 1.93B	$ 1.51B	$ 1.55B	$ 1.32B	$ 1.16B	$ 889.58M
Net Income From Continuing And Discontinued Operation	$ -800.53M	$ -228.65M	$ -852.82M	$ -858.28M	$ -886.12M	$ -761.50M
Normalized Income	$ -554.00M	-	$ -865.43M	$ -885.19M	$ -894.36M	$ -779.11M
Interest Expense	$ 83.69M	-	$ 143.02M	$ 84.50M	$ 0.00	$ 0.00
EBIT	$ -670.69M	$ -971.02M	$ -709.12M	$ -771.10M	$ -885.25M	$ -760.67M
EBITDA	$ -596.90M	$ -929.94M	$ -619.43M	$ -736.33M	$ -868.08M	$ -745.43M

Currency in USD

Alnylam Pharma Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing